0

The atypically popular atypical antipsychotics

We know one thing for sure that’s typical for the atypical (or second generation) antipsychotics. They’ve caught on like a house on fire. The atypicals are the top-selling class of drugs today, with revenues in 2010 of about $14.6 billion and $18.2 billion… Continue Reading

0

Atypical Attitudes: How The Atypicals Took the Fall in Dementia Patients–The Other Meds Catch Up

In 2008, the FDA put out the following: “For Immediate Release: FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs.” It said: The U.S. Food and Drug Administration today exercised its new authority . . .to require manufacturers of… Continue Reading

0

The Bipolar Road Less Traveled: Beyond Lithium, Part I

Once upon a time, if you were diagnosed with bipolar disorder, you were treated with lithium. And, once upon a time, it worked. According to the Report of the Surgeon General, “Success rates of 80 to 90 percent were once… Continue Reading